Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu
View: Text | PDF
Research Article Cell biology Oncology

Notch1 O-GlcNAcylation drives tumor stemness and mechanoadaptation to a stiff microenvironment and promotes chordoma recurrence

  • Text
  • PDF
Abstract

Chordomas are rare malignant osseous neoplasms with a striking rate of recurrence. Primary chordomas typically originate from embryonic notochord remnants, whereas recurrent chordomas usually stem from tumor cells infiltrating bone or cartilage after surgery. Clinically, the recurrent chordomas exhibit a stiffer extracellular microenvironment (ECM) than primary tumors. Intriguingly, this study identified cytoskeleton rearrangement, stress fiber reorganization, enhanced stemness, and Notch signaling activation in recurrent chordoma tissues or cell lines surviving stiff substrates, indicating the critical roles of mechanical remodeling and tumor stemness in stiffness resistance. We propose a potentially novel recurrence model where tumor cells experience mechanoadaptive organization, which enables them to resist stiff microenvironment-induced cell death. O-GlcNAcylation of Notch1 intracellular domain (NICD1) is central to this process. Mechanistically, the stiff ECM-driven ligand-independent phosphorylation of EPHA2 sequentially activated LYN kinase and subsequently triggered O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) activity by phosphorylating Y989 and Y418, critical residues for OGT glycosyltransferase activity; this induced NICD1 O-GlcNAcylation at T2063, T2090, and S2162, specifically promoting transcription of mechanical and stemness-related genes. MIR31 deletion upregulated LYN, enhancing stiffness perception and promoting O-GlcNAc addition to NICD1, finally resulting in mechanoadaptation- and tumor stemness–driven recurrence. Consequently, MIR31 deletion is a potential biomarker for recurrence and patient stratification in Notch- or OGT-targeted therapies.

Authors

Chengjie Lian, Weiyan Peng, Peiqiang Su, Yan Ye, Jialing Liu, Dongsheng Huang, Xuejuan Sun, Yi Pu, Zhiheng Liao, Xudong Wang, Zhu Qiu, Shanshan Wu, Lei Liu

×

Figure 2

Increased NICD1 O-GlcNAcylation contributes to aberrant Notch signaling activation in recurrent chordoma.

Options: View larger image (or click on image) Download as PowerPoint
Increased NICD1 O-GlcNAcylation contributes to aberrant Notch signaling ...
(A) IHC was used to assess levels of global O-GlcNAc and NICD1 in established NP and chordoma cell lines. (B) IP was used to analyze NICD1-specific O-GlcNAcylation levels. (C) Detection of NICD1 O-GlcNAcylation by the Click-iT O-GlcNAc Enzymatic Labeling System. (D) GFP to assess the effect of PUGNAC (50 μM, 24 hours) and GlcNAc (10 μM, 24 hours) treatment on Notch signaling activity. JAG-1 (40 μM, 24 hours) was used as the positive control in activating Notch signaling. Scale bar: 50 μm. (E) IHC was used to assess expression of O-GlcNAc expression in early- (n = 55) and late-stage (n = 32) chordoma. Scale bar: 100 μm. (F and G) Duolink PLA was used to assess NICD1-specific O-GlcNAc in clinical specimens (F, n = 10 pairs). NICD1 and global O-GlcNAc expression was detected using IF assay, and the correlation between global O-GlcNAc expression and NICD1-specific O-GlcNAc expression was analyzed (G, n = 20). Scale bar: 50 μm. The black dotted line shows the median value of Duolink, while the green and orange lines indicate the median values of NICD1 and global O-GlcNAc, respectively. (H) Kaplan-Meier analysis of recurrence-free survival. The NICD1-specific O-GlcNAc level was assessed using Duolink PLA in specimens. Median survival time and horizon risk (HR) of recurrence were listed. (I) Duolink PLA detects NICD1-specific O-GlcNAc in chordoma cells surviving substrates with different stiffnesses at 48 hours. Scale bar: 1 μm. (J and K) Colony-formation and TUNEL assay results from cells cultured on substrates with different stiffnesses and indicated treatment. Cells were cultured and treated with PUGNAC (50 μM), GlcNAc (10 μM), and DAPT (20 μM) for 7 days (J) or 48 hours (K). (L) TUNEL assay and qPCR results from cells cultured on collagen, with periodic stress stimulation to determine the effects on cell death (as described in the legend for Figure 1O). Data in J–L are presented as mean ± SD. Statistical analysis was performed using χ2 test (E), paired Student’s t test (F), and 1-way ANOVA (J–L). *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts